Leave ‘Lena’ for the really needy, the rest should zip up or pay up
Lenacapavir, which is primarily targeted at commercial sex workers and discordant couples, is now much sought after by (often well-to-do) men, and the doses ran out in next to no time.
When America’s regulators earlier this year approved an injectable that protects a person from contracting HIV which is administered twice a year, all people of goodwill had reason to applaud. Soon after, this magic bullet called Lenacapavir was launched in Uganda, with distribution of the initial 19,200 doses starting in June at some 100 health centres in Uganda.
It is highly likely that no new product has been so ferociously snapped up like Lenacapavir. Even vaccines for Covid-19, a quick killing disease which you could catch by doing the inevitable, that is breathing, were not as fervently sought after. Lenacapavir, which is primarily targeted at commercial sex workers and discordant couples, is now much sought after by (often well-to-do) men, and the doses ran out in next to no time.
